Previous Close | 3.1900 |
Open | 3.2000 |
Bid | 3.4900 x 1800 |
Ask | 3.5000 x 4000 |
Day's Range | 3.2000 - 3.5750 |
52 Week Range | 2.4900 - 5.5300 |
Volume | |
Avg. Volume | 3,554,057 |
Market Cap | 886.934M |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3230 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square. The ceremony will begin at a
V-Go® acquired by MannKind Corporation MannKind Corporation announced today an agreement to acquired V-Go® insulin delivery device from Zealand Pharma. V-Go is a once-daily insulin delivery device that strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions. The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind C
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD. 2022 RBC Capital Markets Global Healthcare Conference – Tuesday, May 17, 2022